CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 1294 of 1294 entries

View as:

A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range

Phase: N/A Priority: Normal

NCT ID: NCT06041217 Org: User:

Start: 09/15/23 End: 05/07/25 Due: 05/07/26

A Study on How NNC0174-1213 Works in People With Overweight or Obesity.

Phase: N/A Priority: Normal

NCT ID: NCT06719011 Org: User:

Start: 12/03/24 End: 05/17/26 Due: 05/17/27

Effect of Food on the Pharmacokinetics of NNC0123-0000-0338 in a Tablet Formulation in Healthy Subjects

Phase: N/A Priority: Normal

NCT ID: NCT02304627 Org: User:

Start: 11/24/14 End: 07/31/15 Due: 07/31/16

Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes

Phase: N/A Priority: Normal

NCT ID: NCT00605020 Org: User:

Start: 12/02/03 End: 03/03/05 Due: 03/03/06

Observational Study With InnoLet® in Daily Clinical Practice

Phase: N/A Priority: Normal

NCT ID: NCT01492959 Org: User:

Start: 03/23/04 End: 03/23/05 Due: 03/23/06

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III

Phase: N/A Priority: Normal

NCT ID: NCT06097390 Org: User:

Start: 09/28/23 End: 03/27/24 Due: 03/27/25

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice

Phase: N/A Priority: Normal

NCT ID: NCT05443568 Org: User:

Start: 03/09/23 End: 11/03/24 Due: 11/03/25

Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes

Phase: N/A Priority: Normal

NCT ID: NCT01917656 Org: User:

Start: 01/09/14 End: 09/04/14 Due: 09/04/15

SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

Phase: N/A Priority: Normal

NCT ID: NCT04287179 Org: User:

Start: 03/09/20 End: 01/25/21 Due: 01/25/22

A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 2 Diabetes

Phase: N/A Priority: Normal

NCT ID: NCT01467414 Org: User:

Start: 10/31/11 End: 12/31/11 Due: 12/31/12

Comparison of Efficacy and Safety of Repaglinide Combined With Insulin NPH Versus Biphasic Human Insulin 30 Alone in Inadequately Controlled Subjects With Type 2 Diabetes

Phase: N/A Priority: Normal

NCT ID: NCT00799448 Org: User:

Start: 09/16/03 End: 09/20/04 Due: 09/20/05

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice

Phase: N/A Priority: Normal

NCT ID: NCT05230615 Org: User:

Start: 11/21/21 End: 11/03/23 Due: 11/03/24

Pharmacokinetics of Somatropin in Patients With End Stage Renal Disease Receiving Chronic Haemodialysis

Phase: N/A Priority: Normal

NCT ID: NCT01502137 Org: User:

Start: 06/30/05 End: 11/30/05 Due: 11/30/06

First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects

Phase: N/A Priority: Normal

NCT ID: NCT01514500 Org: User:

Start: 01/16/12 End: 03/18/13 Due: 03/18/14

An International Survey of the Occurrence of Cardiovascular Disease Among Patients With Type 2 Diabetes

Phase: N/A Priority: Normal

NCT ID: NCT03811288 Org: User:

Start: 12/10/18 End: 09/30/19 Due: 09/30/20

A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters

Phase: N/A Priority: Normal

NCT ID: NCT06709040 Org: User:

Start: 12/13/24 End: 04/14/34 Due: 04/14/35

Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition

Phase: N/A Priority: Normal

NCT ID: NCT03926117 Org: User:

Start: 06/03/19 End: 06/26/20 Due: 06/26/21

Use of Somatropin in Turner Syndrome

Phase: N/A Priority: Normal

NCT ID: NCT01518036 Org: User:

Start: 09/14/87 End: 04/11/04 Due: 04/11/05

Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos

Phase: N/A Priority: Normal

NCT ID: NCT01542489 Org: User:

Start: 10/31/06 End: 04/30/07 Due: 04/30/08

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range	NCT06041217	Novo Nordisk A/S	user2@example.com	None	2023-09-15	2025-05-07	2026-05-07	-	-	2025-07-14
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.	NCT06719011	Novo Nordisk A/S	user2@example.com	None	2024-12-03	2026-05-17	2027-05-17	-	-	2025-07-14
Effect of Food on the Pharmacokinetics of NNC0123-0000-0338 in a Tablet Formulation in Healthy Subjects	NCT02304627	Novo Nordisk A/S	user2@example.com	None	2014-11-24	2015-07-31	2016-07-31	-	-	2025-07-14
Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes	NCT00605020	Novo Nordisk A/S	user2@example.com	None	2003-12-02	2005-03-03	2006-03-03	-	-	2025-07-14
Observational Study With InnoLet® in Daily Clinical Practice	NCT01492959	Novo Nordisk A/S	user2@example.com	None	2004-03-23	2005-03-23	2006-03-23	-	-	2025-07-14
A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III	NCT06097390	Novo Nordisk A/S	user2@example.com	None	2023-09-28	2024-03-27	2025-03-27	-	-	2025-07-14
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice	NCT05443568	Novo Nordisk A/S	user2@example.com	None	2023-03-09	2024-11-03	2025-11-03	-	-	2025-07-14
Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes	NCT01917656	Novo Nordisk A/S	user2@example.com	None	2014-01-09	2014-09-04	2015-09-04	-	-	2025-07-14
SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes	NCT04287179	Novo Nordisk A/S	user2@example.com	None	2020-03-09	2021-01-25	2022-01-25	-	-	2025-07-14
A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 2 Diabetes	NCT01467414	Novo Nordisk A/S	user2@example.com	None	2011-10-31	2011-12-31	2012-12-31	-	-	2025-07-14
Comparison of Efficacy and Safety of Repaglinide Combined With Insulin NPH Versus Biphasic Human Insulin 30 Alone in Inadequately Controlled Subjects With Type 2 Diabetes	NCT00799448	Novo Nordisk A/S	user2@example.com	None	2003-09-16	2004-09-20	2005-09-20	-	-	2025-07-14
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice	NCT05230615	Novo Nordisk A/S	user2@example.com	None	2021-11-21	2023-11-03	2024-11-03	-	-	2025-07-14
Pharmacokinetics of Somatropin in Patients With End Stage Renal Disease Receiving Chronic Haemodialysis	NCT01502137	Novo Nordisk A/S	user2@example.com	None	2005-06-30	2005-11-30	2006-11-30	-	-	2025-07-14
First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects	NCT01514500	Novo Nordisk A/S	user2@example.com	None	2012-01-16	2013-03-18	2014-03-18	-	-	2025-07-14
An International Survey of the Occurrence of Cardiovascular Disease Among Patients With Type 2 Diabetes	NCT03811288	Novo Nordisk A/S	user2@example.com	None	2018-12-10	2019-09-30	2020-09-30	-	-	2025-07-14
A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters	NCT06709040	Novo Nordisk A/S	user2@example.com	None	2024-12-13	2034-04-14	2035-04-14	-	-	2025-07-14
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition	NCT03926117	Novo Nordisk A/S	user2@example.com	None	2019-06-03	2020-06-26	2021-06-26	-	-	2025-07-14
Use of Somatropin in Turner Syndrome	NCT01518036	Novo Nordisk A/S	user2@example.com	None	1987-09-14	2004-04-11	2005-04-11	-	-	2025-07-14
Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos	NCT01542489	Novo Nordisk A/S	user2@example.com	None	2006-10-31	2007-04-30	2008-04-30	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance